Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Dose Fractionation. Found 16 abstracts

Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Wang LS, Handorf EA, Wu H, Liu JC, Perlis CS, Galloway TJ. Surgery and Adjuvant Radiation for High-risk Skin Adnexal Carcinoma of the Head and Neck. Am J Clin Oncol. 2017 Aug;40(4):429-32.   PMCID: PMC4504824
Zaorsky NG, Williams GR, Barta SK, Esnaola NF, Kropf PL, Hayes SB, Meyer JE. Splenic irradiation for splenomegaly: A systematic review. Cancer Treat Rev. 2017 Feb;53:47-52.
Tong X, Chen XM, Li JS, Xu QQ, Lin MH, Chen LL, Price RA, Ma CM. Intrafractional prostate motion during external beam radiotherapy monitored by a real-time target localization system. J Appl Clin Med Phys. 2015 Mar 08;16(2):51-61.
Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Practical radiation oncology. 2015 Sep;5(5):e457-63.   PMCID: 4814166
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan 10;33(2):156-64.   PMCID: PMC4279235
Li J, Lang J, Wang P, Kang S, Lin MH, Chen X, Chen F, Guo M, Chen L, Ma CM. Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques. Medical Dosimetry. 2014 Jan;39(4):330-6.
Turaka A, Parsons RB, Buyyounouski MK. Radiation therapy for pituitary metastasis: report of four cases. Tumori. 2012 Jan;98(1):e1-6.   PMCID: Not NIH funded
Ma CM, Luxton G, Orton CG. Point/counterpoint: pulsed reduced dose rate radiation therapy is likely to become the treatment modality of choice for recurrent cancers. Med Phys. 2011 Sep;38(9):4909-11.   PMCID: not NIH funded
Cohen RJ, Paskalev K, Litwin S, Price RA, Feigenberg SJ, Konski AA. Esophageal motion during radiotherapy: quantification and margin implications. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2010 Aug;23(6):473-9.   PMCID: PMC2933373
Konski AA, Winter K, Cole BF, Ang KK, Fu KK. Quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head & neck. 2009 Feb;31(2):207-12.
Li JS, Jin L, Pollack A, Horwitz EM, Buyyounouski MK, Price RA, Ma CM. Gains from real-time tracking of prostate motion during external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Dec;75(5):1613-20.
Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys. 2007 Mar 20;68(2):347-53.
Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003 Jan;123(1 Suppl):221S-225S.
Holland J. New treatment modalities in radiation therapy. J Intraven Nurs. 2001 Mar;24(2):95-101.
Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients. Int J Radiat Oncol Biol Phys. 2000 Dec;48(5):1351-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Dose Fractionation

Dose Fractionation radiotherapy methods Male Middle Aged Female Aged pathology Computer-Assisted Radiotherapy Planning Combined Modality Therapy Adult therapeutic use 80 and over Aged mortality therapy adverse effects Prostatic Neoplasms Tumor Burden Radiotherapy Intensity-Modulated Radiotherapy Movement Local Neoplasm Recurrence Treatment Outcome Neoplasm Staging Retrospective Studies Follow-Up Studies Head and Neck Neoplasms Patient Selection Non-Small-Cell Lung Carcinoma Lung Neoplasms Pancreatic Neoplasms drug therapy Disease-Free Survival Prostate Prospective Studies Chemoradiotherapy Radiotherapy Dosage Adenocarcinoma Antineoplastic Agents complications Human secondary surgery instrumentation Neoplasms radiography Conformal Radiotherapy X-Ray Computed Tomography Squamous Cell Carcinoma Four-Dimensional Computed Tomography Area Under Curve Breast Neoplasms Reirradiation Adjuvant Chemoradiotherapy Magnetic Resonance Imaging Hematologic Neoplasms Tumor Biomarkers Proto-Oncogene Proteins c-bcl-2 Intraductal Carcinoma-Noninfiltrating Radiometry Palliative Care Confusion genetics etiology Adnexal and Skin Appendage Neoplasms Feasibility Studies Brain Neoplasms Radiation oncology Deglutition Disorders Medical Records Stereotaxic Techniques radiation effects Myelofibrosis Androgen Antagonists Meta-analysis Alkylating Antineoplastic Agents Palliation diagnosis Inflammatory Breast Neoplasms Treatment Failure Quality of Life Carmustine Cyclin-Dependent Kinase Inhibitor p16 chemistry Prostate-Specific Antigen trends Recurrence Radiation-Sensitizing Agents Lymph Node Excision Rotation Adjuvant Radiotherapy Smoking Neck Dissection Brachytherapy analysis Diplopia Radiation Dosage Leukemia Tumor Suppressor Protein p53 Hormonal Antineoplastic Agents Relative Biological Effectiveness Calibration Neoadjuvant Therapy Radiosurgery Imrt Pituitary Neoplasms Proto-Oncogene Proteins c-mdm2 ROC Curve Kaplan-Meier Estimate Esophageal Neoplasms Physiologic Monitoring Glioblastoma Ductal Carcinoma-Breast Pulsed low dose rate (PLDR) Lymphoma diagnostic imaging bcl-2-Associated X Protein Spleen Radiation-Protective Agents Splenomegaly Cancer Cyclooxygenase 2 Ki-67 Antigen nursing Headache Esophagus Survival Analysis Computer Systems Toxicity Fatal Outcome blood Cisplatin
Last updated on Saturday, August 15, 2020